Is there a dose-response relationship of metformin treatment in patients with polycystic ovary syndrome? Results from a multicentric study
Open accessThe DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
STUDY QUESTION: Do different dosages of metformin account for different clinical and biochemical outcomes in women with polycystic ovary syndrome (PCOS) and do basal anthropometric and metabolic characteristics of the patients provide any indications regarding the dose required to reach the target effect? SUMMARY ANSWER: Different doses of metformin exerted the same effects on clinical, biochemical and metabolic parameters in patients affected by PCOS. WHAT IS KNOWN AND WHAT THIS PAPER ADDS: Since the insulin-sensitizing agents came into use in the management of PCOS, metformin has shown a positive benefits-risks ratio. Nonetheless, therapeutic schedules are not well standardized. This is the first study which systematically analyses the effect of different doses of metformin on clinical, hormonal and metabolic features of PCOS. On the basis of our results, higher doses are no more effective than lower doses. DESIGN: A multicentric cohort prospective study. A total of 250 PCOS women were enrolled, 49 lost to follow-up. Menstrual cyclicity, hormonal assays, oral glucose tolerance test, lipid profile and ultrasonographic pelvic examination were evaluated at the baseline and after 6 months of metformin treatment at different doses (1000, 1500 and 1700 mg). PARTICIPANTS AND SETTING: A total of 201 PCOS patients completed the study without protocol violations in three university hospitals: seventy-three patients from Centre A (treated with metformin 500 mg twice a day), 60 patients from Centre B (treated with metformin 500 mg three times a day) and 68 patients from Centre C (treated with metformin 850 mg twice a day). MAIN RESULTS AND THE ROLE OF CHANCE: Metformin exerted an overall positive effect on the clinical and endocrine-metabolic features of PCOS. The degree of these effects was independent of the administered dosage in every range of basal body mass index (BMI). When patients were stratified according to their insulinaemic status, scattered inter-doses differences were found in some of the outcome measures. Patients who exhibited an increase of >2 menstrual cycles/year were considered as responders to treatment. Responders had a higher basal BMI than non-responders and showed a greater reduction in plasma testosterone levels after metformin treatment, but other outcome measures did not differ significantly. Total insulin secretion in the 180 min following the glucose tolerance test before metformin treatment (basal AUC-I) was significantly correlated with the decrease in insulin secretion induced by metformin in both the whole group and in responders, but only correlated with the variation in the number of cycles in responders. BIAS, CONFOUNDING AND OTHER REASONS FOR CAUTION: The different doses were administered in different centres, and between-centre variation is a potential confounding factor. GENERALIZABILITY TO OTHER POPULATIONS: The paradigm of using the minimum effective dose of metformin could be pursued in other pathological conditions characterized by insulin resistance. STUDY FUNDING/COMPETING INTEREST(S): No funding or competing interests to declare.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, metformin may induce mild to severe gastrointestinal side effects such as nausea, diarrhea, vomiting, and flatulence [11].”
From Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials (2023) · cites this paper as [11]
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502 · cited 3×
“The evaluation of insulin sensitivity was made by the homeostatic index (HOMA), which was calculated as follows: HOMA 1⁄4 [fasting insulin (mU/ ml) × fasting glucose (mmol/l)/22, 5] (Matthews et al., 1985).”
MethodInfluentialClassification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
Ehrmann, D. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041536 · Cited by 1,881
Teede, H., Deeks, A., & Moran, L. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-41 · Cited by 1,565 · cited 2×
“50% of PCOS women, is the most important determinant of insulin resistance and hyperinsulinaemia, which, nevertheless, also affects 30% of normal weight subjects (Ciampelli and Lanzone, 1998) The high circulating levels of insulin act at various levels of the hypothalamic–pituitary–ovarian axis, as well as on the hepa…”
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome
Legro, R. S., Barnhart, H. X., Schlaff, W. D., Carr, B. R., Diamond, M. P., Carson, S. A., Steinkampf, M. P., Coutifaris, C., McGovern, P. G., Cataldo, N. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063971 · Cited by 1,027 · cited 1×
“The most commonly reported side effects are nausea, vomiting and gastrointestinal distress, such as diarrhoea, flatulence and abdominal discomfort (Legro et al., 2007; Tang et al., 2012).”
BackgroundPrevalence and Characteristics of the Metabolic Syndrome in Women with Polycystic Ovary Syndrome
Apridonidze, T., Essah, P. A., Iuorno, M. J., & Nestler, J. E. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1045 · Cited by 931
Velazquez, E. M., Mendoza, S., Hamer, T., Sosa, F., & Glueck, C. J. (1994) · Metabolism · doi:10.1016/0026-0495(94)90209-7 · Cited by 865 · cited 1×
“Since the first report in 1994 (Velazquez et al., 1994), .500 original studies on metformin administration in PCOS have been published: most of them reported an improvement in insulin sensitivity, body mass index (BMI) and menstrual pattern, and a decrease in androgen levels (Moghetti et al., 2000).”
BackgroundNestler, J. E., Jakubowicz, D. J., Evans, W. S., & Pasquali, R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199806253382603 · Cited by 784 · cited 2×
“This finding is in line with some and in contrast to other studies in the literature: some authors, indeed, documented that metformin may restore ovarian function regardless of BMI (Nestler and Jakubowicz, 1996; Nestler and Jakubowicz, 1997; Nestler et al., 1998), whilst others reported that lower BMI was more likely…”
BackgroundResultSelf-citationNestler, J. E., & Jakubowicz, D. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350902 · Cited by 743 · cited 1×
“…and in contrast to other studies in the literature: some authors, indeed, documented that metformin may restore ovarian function regardless of BMI (Nestler and Jakubowicz, 1996; Nestler and Jakubowicz, 1997; Nestler et al., 1998), whilst others reported that lower BMI was more likely associated…”
ResultTang, T., Lord, J. M., Norman, R. J., Yasmin, E., & Balen, A. H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003053.pub5 · Cited by 698
Research works printed but not linked: 1
- Moghetti, 2000, Journal of Clinical Endocrinology & Metabolism, 85, 139, 10.1210/jc.85.1.139 · doi:10.1210/jc.85.1.139 · Paper page
Cited by
Greff, D., Juhász, A. E., Váncsa, S., Váradi, A., Sipos, Z., Szinte, J., Park, S., Hegyi, P., Nyirády, P., Ács, N., et al. (2023) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-023-01055-z · Cited by 143
“However, metformin may induce mild to severe gastrointestinal side effects such as nausea, diarrhea, vomiting, and flatulence [11].”
BackgroundXing, C., Zhang, J., Zhao, H., & He, B. (2022) · International Journal of Women's Health · doi:10.2147/ijwh.s344542 · Cited by 118
“The observed poor compliance has prompted clinicians worldwide to find new ways to treat PCOS.(79) Table 1 Characteristics of the Included RCTs of Intervention on Changes of Serum SHBG”
BackgroundFavourable metabolic effects of a eucaloric lower‐carbohydrate diet in women with PCOS
Gower, B. A., Chandler‐Laney, P. C., Ovalle, F., Goree, L. L., Azziz, R., Desmond, R. A., Granger, W. M., Goss, A. M., & Bates, G. W. (2013) · Clinical Endocrinology · doi:10.1111/cen.12175 · Cited by 108
Facchinetti, F., Orrù, B., Grandi, G., & Unfer, V. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1540578 · Cited by 94
“However, its use may be limited by significant side effects such as nausea, vomiting, and gastrointestinal discomfort [8].”
BackgroundMetformin: The hidden chronicles of a magic drug
Mahmood, K., Naeem, M., & Rahimnajjad, N. A. (2012) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2012.10.011 · Cited by 87
“Metformin affects the cardiometabolic parameters independent of the dosage administered [39].”
BackgroundPalomba, S., Falbo, A., & La Sala, G. B. (2014) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-12-3 · Cited by 78
“These differences in metformin doses could again bias our findings, although recent data [35] demonstrated the lack of significant difference between metformin doses and treatment effectiveness even at lower dosages.”
ResultAbdou, H. S., Bergeron, F., & Tremblay, J. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00734-14 · Cited by 85
“Interestingly, androgen levels in women suffering from PCOS or breast cancer treated with metformin are decreased (72, 73), suggesting that metformin improves the health of these patients by repressing steroidogenesis via AMPK activation.”
BackgroundMirmasoumi, G., Fazilati, M., Foroozanfard, F., Vahedpoor, Z., Mahmoodi, S., Taghizadeh, M., Esfeh, N. K., Mohseni, M., Karbassizadeh, H., & Asemi, Z. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-119751 · Cited by 64
Baicalin ameliorates polycystic ovary syndrome through AMP-activated protein kinase
Wang, W., Zheng, J., Cui, N., Jiang, L., Zhou, H., Zhang, D., & Hao, G. (2019) · Journal of Ovarian Research · doi:10.1186/s13048-019-0585-2 · Cited by 57
“In addition, activation of AMPK by metformin and AICAR could attenuate PCOS-related endocrine and reproductive dysfunction [24].”
BackgroundContemporary approaches to the management of polycystic ovary syndrome
Pasquali, R. (2018) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018818756790 · Cited by 63
Self-citationKaramali, M., Kashanian, M., Alaeinasab, S., & Asemi, Z. (2018) · Journal of Human Nutrition and Dietetics · doi:10.1111/jhn.12545 · Cited by 43
Tao, X., Chen, L., Cai, L., Ge, S., & Deng, X. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.09.154 · Cited by 46
Tagliaferri, V., Romualdi, D., Immediata, V., De Cicco, S., Di Florio, C., Lanzone, A., & Guido, M. (2017) · Clinical Endocrinology · doi:10.1111/cen.13304 · Cited by 40
Self-citationFroment, P., Plotton, I., Giulivi, C., Fabre, S., Khoueiry, R., Mourad, N. I., Horman, S., Ramé, C., Rouillon, C., Grandhaye, J., et al. (2022) · Human Reproduction · doi:10.1093/humrep/deac067 · Cited by 43
Hashim, H. A., Foda, O., & Ghayaty, E. (2015) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.12673 · Cited by 42
“Thirdly, the dose of metformin administered was not completely the same in all trials, which could influence the results; however, recent data demonstrated a lack of significant difference between metformin doses and treatment effectiveness even at lower dosages (48).”
ResultNasri, K., Akrami, S., Rahimi, M., Taghizadeh, M., Behfar, M., Mazandaranian, M. R., Kheiry, A., Memarzadeh, M. R., & Asemi, Z. (2017) · Endocrine Research · doi:10.1080/07435800.2017.1346661 · Cited by 34
RetractedJuhász, A. E., Stubnya, M. P., Teutsch, B., Gede, N., Hegyi, P., Nyirády, P., Bánhidy, F., Ács, N., & Juhász, R. (2024) · Reproductive Health · doi:10.1186/s12978-024-01758-5 · Cited by 32
“Metformin is an insulin sensitiser commonly used in PCOS patients with IR; however, gastro-intestinal side effects limit its use as a first-choice for long-term treatment [7].”
BackgroundForoozanfard, F., Talebi, M., Samimi, M., Mehrabi, S., Badehnoosh, B., Jamilian, M., Maktabi, M., & Asemi, Z. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0043-112346 · Cited by 34
“All participants were taking metformin tablet at the initial dose of 500 mg, which was increased in a stepwise manner during the first 3 weeks to a total of 1 500 mg/ day [14].”
MethodHow Relevant is the Interaction Between Dolutegravir and Metformin in Real Life?
Gervasoni, C., Minisci, D., Clementi, E., Rizzardini, G., & Cattaneo, D. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001292 · Cited by 35
Ma, R., Zou, Y., Wang, W., Zheng, Q., Feng, Y., Dong, H., Tan, Z., Zeng, X., Zhao, Y., Deng, Y., et al. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00848-w · Cited by 22
“A multicenter study reported that metformin administered at 1000mg/day or 1500–1700mg/day showed similar therapeutic effects on the clinical and biochemical parameters of PCOS patients [26].”
BackgroundTalari, H. R., Azad, Z. J., Hamidian, Y., Samimi, M., Gilasi, H. R., Afshar, F. E., Ostadmohammadi, V., & Asemi, Z. (2019) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_2_18 · Cited by 18
“[15] All participants were consuming metformin tablet at the initial dose of 500 mg, which was increased in a stepwise manner during the first 3 weeks to a total of 1500 mg/day.[16] Shape, size, and color of the placebo capsules were identical with the carnitine capsules.”
Roodbari, A. S., Solhjoo, S., Palmerini, M. G., Mansouri, M., & Ezzatabadipour, M. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-023-01244-9 · Cited by 15
“Despite improvements in treatment protocols, long-term drugs such as Met-formin may lead to gastrointestinal problems, diarrhea and other adverse side effects that negatively affect the quality of patients’ life [18, 36].”
BackgroundMahmoud, M. M., Rashed, L. A., Soliman, S. A. M., Sayed, S. M., Kamel, O., Kamar, S. S., & Hussien, R. E. S. (2023) · Physiological Reports · doi:10.14814/phy2.15858 · Cited by 20
“(Fulghesu et al., 2012; Pasquali, 2015).”
What is new in the landscape of insulin-sensitizing agents for polycystic ovary syndrome treatment
Romualdi, D., Versace, V., & Lanzone, A. (2020) · Therapeutic Advances in Reproductive Health · doi:10.1177/2633494120908709 · Cited by 20
Self-citationMyoinositol Versus Metformin in the Treatment of Polycystic Ovarian Syndrome: A Systematic Review
Bodepudi, R., Seher, S., Khan, S. A., Emmanuel, S., Kumar, V. S., Nerella, R., Ameen, B. S., Patel, D., John, J. D., & Khan, S. (2023) · Cureus · doi:10.7759/cureus.41748 · Cited by 19
Wang, J., Huang, Z., Cao, Z., Luo, Y., Liu, Y., Cao, H., Tang, X., & Fang, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011146 · Cited by 12
Vitale, S. G., Michele, S. D., Tassi, A., Succu, C., Angioni, S. L., & Fulghesu, A. M. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03251-2 · Cited by 16
“Specifically, the study group (metformin + COCs) received metformin at a dosage determined according to Fulghesu et al. [30], who demonstrated that “low-dose” metformin (1000 mg/day) has comparable efficacy to higher doses (1500–1700 mg/day).”
InfluentialSelf-citationVeličković, N. A., Mićić, B., Teofilović, A., Milovanovic, M., Jovanović, M., Djordjevic, A. D., Μacut, D., & Milutinović, D. V. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1402905 · Cited by 11
Polycystic Ovary Syndrome Endocrine and Cardio-Metabolic Abnormalities: how to Manage?
Georgescu, C. E. (2015) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2015.77 · Cited by 7
Obesity and Polycystic Ovary Syndrome
Qamar, U., Atkin, S. L., & Sathyapalan, T. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48559-3.00006-3 · Cited by 12
Varikasuvu, S. R., Pérez-López, F. R., Thangappazham, B., Raj, H., & Vykunta, A. (2021) · Gynecological Endocrinology · doi:10.1080/09513590.2021.1998439 · Cited by 6
Cattaneo, D., Formenti, T., Minisci, D., Casalini, G., Meraviglia, P., & Gervasoni, C. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab077 · Cited by 6
Role of Metformin in Polycystic Ovary Syndrome
Nowak, K., Nowak, K., Olejarz, Z., Drygała, Z., Wyrwał, J., Zielińska, Z., Słowik, M., Nieć, M., Gierlach, K., & Krasuska, M. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.52.009 · Cited by 6
“[7] Furthermore, it's worth noting that while metformin is approved as a first-line therapy for Type 2 diabetes mellitus, its use in PCOS is considered off-label.”
BackgroundIs Metformin the Answer for Distressed Females with Menstrual Irregularities?
Tejpal, C., Poudel, I., & Jahan, N. (2019) · Cureus · doi:10.7759/cureus.5460 · Cited by 4
“DOI 10.7759/cureus.5460 3 of 7 Randomized Controlled Trial Author/Year Population Metformin (dose in mg if applicable) Arms Length of Study (Months) Results Menses LH/FSH Weight Testosterone Other Seyam et al.”
InfluentialExplore the Relationship between Insulin Resistance and PGC1α in PCOS Mice
Chen, L., Tao, X., Ge, S., Cai, L., & Deng, X. (2018) · Open Journal of Endocrine and Metabolic Diseases · doi:10.4236/ojemd.2018.83008 · Cited by 3
“PCOS patients are often accompanied by insulin resistance (IR), and IR is closely related to reproductive dysfunction such as infertility and habitual abortion [2].”
BackgroundSpritzer, P. M. (2015) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.1590/so100-720320140005212 · Cited by 4
Shibli-Rahhal, A. A., Haynes, W. G., Sinkey, C. A., & Dillon, J. S. (2012) · journal of Diabetes Research and Clinical Metabolism · doi:10.7243/2050-0866-1-13 · Cited by 2
“One possible explanation is the fact that 55% (5/9) diabetic subjects were on metformin while none of the controls took metformin, which has been shown to decrease total testosterone [37].”
BackgroundRastegar, F., Rezaee, Z., Saedi, N., Memari, R., & Tajpour, M. (2021) · Biomedical Research and Therapy · doi:10.15419/bmrat.v8i12.710 · Cited by 2
Saghafi, F., Javaheri, A., Mohammadi, F., Hatamizadeh, N., Khanizadeh, F., Safakish, M., & Sahebnasagh, A. (2025) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-025-00432-7 · Cited by 2
“However, various studies reported the bothersome gastrointestinal side effects of this medication such as flatulence, vomiting and nausea [10].”
A multidisciplinary approach to polycystic ovary syndrome: synergy of methods
Andreeva, E. N., Mel'nichenko, G. A., Yarmolinskaya, M. I., Khamoshina, M. B., Сутурина, Л. В., Фархадовна, Б. Ф., Grigoryan, O. R., Sukhareva, O. Y., Tiselko, A. V., Vorotnikova, S. Y., et al. (2025) · Bulletin of Reproductive Health · doi:10.14341/brh12779 · Cited by 1
Kumar, M., Thukral, A., Jain, R. K., CHAUDHARY, S. K., Mukherjee, S., & Chowdhury, S. (2013) · Clinical Endocrinology · doi:10.1111/cen.12214
Síndrome dos ovários policísticos e doença hepática gordurosa não alcóolica: o que sabemos?
Pinto, F. H. A. D. M., Nardelli, M. J., Elias, M. L. C., Santos, B. C., Couto, C. A., Rocha, A. L. L., & Faria, L. C. (2019) · Revista Médica de Minas Gerais · doi:10.5935/2238-3182.20190033
Douki, T., Ravanat, J., Markovitsi, D., & Sage, É. (2012) · Dialnet (Universidad de la Rioja)
Polycystic Ovary Syndrome: An Update on Management Strategies
Aftab, M., Inzamam, M., & Latif, S. (2022) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs22164654 · Cited by 1
Metformin for endothelial dysfunction in non-diabetic disorders: a scoping review
van Rensburg, R., Schoonees, A., Ali, M. W., van Zyl, G. U., & Decloedt, E. H. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-100017
“In comparison, the studies without an active comparator (placebo or pre–post metformin assessment) reported significant results favouring metformin Open access in 83.3% (30/36) of studies, accentuating potential bias and confounding.”
InfluentialGreff, D., Juhász, A. E., Váncsa, S., Váradi, A., Sipos, Z., Szinte, J., Park, S., Hegyi, P., Nyírády, P., Ács, N., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22601932
Ma, R., Zou, Y., Wang, W., Zheng, Q., Feng, Y., Dong, H., Tan, Z., Zeng, X., Zhao, Y., Deng, Y., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16575594
Juhász, A. E., Stubnya, M. P., Teutsch, B., Gede, N., Hegyi, P., Nyírády, P., Bánhidy, F., Ács, N., & Juhász, R. (2024) · Figshare · doi:10.6084/m9.figshare.25271775
Metadata
- Authors
- Fulghesu, A. M., Romualdi, D., Di Florio, C., Sanna, S., Tagliaferri, V., Gambineri, A., Tomassoni, F., Minerba, L., Pasquali, R., & Lanzone, A.
- Affiliations
- University of Cagliari (IT)
- Università Cattolica del Sacro Cuore (IT)
- IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
- Corresponding author
- Romualdi, D.
- Venue
- Human Reproduction
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-07-10
- Volume
- 27
- Issue
- 10
- Pages
- 3057-3066
- ISSN
- 0268-1161 (ISSN-L)
- 1460-2350
- OpenAlex
- W2155450883
- Cited by
- 48
- References
- 41
- Citations by year
- 2025: 4 · 2024: 5 · 2023: 5 · 2022: 3 · 2021: 5 · 2020: 1 · 2019: 5 · 2018: 3 · 2017: 7 · 2015: 3 · 2014: 2 · 2013: 2 · 2012: 3
- FWCI
- 3.74
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- Human Reproduction (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Keywords
- metformin, polycystic ovary syndrome, dose-response relationship, insulin sensitizers, menstrual cyclicity, insulin resistance, insulin secretion, testosterone, body mass index, oral glucose tolerance test, lipid profile, insulin-sensitizing therapy, predictors of treatment response, dose standardization
- MeSH terms
- Adult, Dose-Response Relationship, Drug, Female, Glucose Tolerance Test, Humans, Hypoglycemic Agents, Menstrual Cycle, Metformin, Polycystic Ovary Syndrome, Body Mass Index, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.